File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy of vasopressin, steroid, and epinephrine protocol for in-hospital cardiac arrest resuscitation: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis

TitleEfficacy of vasopressin, steroid, and epinephrine protocol for in-hospital cardiac arrest resuscitation: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis
Authors
Issue Date1-Sep-2022
Citation
Journal of Geriatric Cardiology, 2022, v. 19, n. 9, p. 705-711 How to Cite?
Abstract

OBJECTIVES To assess the effect of vasopressin, steroid and epinephrine (VSE) combination therapy on return of spontaneous circulation (ROSC) after in-hospital cardiac arrest (IHCA), and test the conclusiveness of evidence using trial sequential analysis (TSA). METHODS The systematic search included PubMed, EMBASE, Scopus, and Cochrane Central Register of Controlled Trials. Randomized controlled trials (RCTs) that included adult patients with IHCA, with at least one group receiving combined VSE therapy were selected. Data was extracted independently by two reviewers. The main outcome of interest was ROSC. Other outcomes included survival to hospital discharge or survival to 30 and 90 days, with good neurological outcomes. RESULTS We included a total of three RCTs (n = 869). Results showed that VSE combination therapy increased ROSC (risk ratio = 1.41; 95% CI: 1.25-1.59) as compared to placebo. TSA demonstrated that the existing evidence is conclusive. This was also validated by the alpha-spending adjusted relative risk (1.32 [1.16, 1.49], P < 0.0001). Other outcomes could not be meta-analysed due to differences in timeframe in the included studies. CONCLUSIONS VSE combination therapy administered in cardiopulmonary resuscitation led to improved rates of ROSC. Future trials of VSE therapy should evaluate survival to hospital discharge, neurological function and long-term survival.


Persistent Identifierhttp://hdl.handle.net/10722/354496
ISSN
2023 Impact Factor: 1.8
2023 SCImago Journal Rankings: 0.509

 

DC FieldValueLanguage
dc.contributor.authorSatti, Danish Iltaf-
dc.contributor.authorLee, Yan Hiu Athena-
dc.contributor.authorLeung, Keith Sai Kit-
dc.contributor.authorHui, Jeremy Man Ho-
dc.contributor.authorKot, Thompson Ka Ming-
dc.contributor.authorBabar, Arslan-
dc.contributor.authorMahalwar, Gauranga-
dc.contributor.authorWai, Abraham K.C.-
dc.contributor.authorLiu, Tong-
dc.contributor.authorRoever, Leonardo-
dc.contributor.authorTse, Gary-
dc.contributor.authorChan, Jeffrey Shi Kai-
dc.date.accessioned2025-02-11T00:40:13Z-
dc.date.available2025-02-11T00:40:13Z-
dc.date.issued2022-09-01-
dc.identifier.citationJournal of Geriatric Cardiology, 2022, v. 19, n. 9, p. 705-711-
dc.identifier.issn1671-5411-
dc.identifier.urihttp://hdl.handle.net/10722/354496-
dc.description.abstract<p>OBJECTIVES To assess the effect of vasopressin, steroid and epinephrine (VSE) combination therapy on return of spontaneous circulation (ROSC) after in-hospital cardiac arrest (IHCA), and test the conclusiveness of evidence using trial sequential analysis (TSA). METHODS The systematic search included PubMed, EMBASE, Scopus, and Cochrane Central Register of Controlled Trials. Randomized controlled trials (RCTs) that included adult patients with IHCA, with at least one group receiving combined VSE therapy were selected. Data was extracted independently by two reviewers. The main outcome of interest was ROSC. Other outcomes included survival to hospital discharge or survival to 30 and 90 days, with good neurological outcomes. RESULTS We included a total of three RCTs (n = 869). Results showed that VSE combination therapy increased ROSC (risk ratio = 1.41; 95% CI: 1.25-1.59) as compared to placebo. TSA demonstrated that the existing evidence is conclusive. This was also validated by the alpha-spending adjusted relative risk (1.32 [1.16, 1.49], P < 0.0001). Other outcomes could not be meta-analysed due to differences in timeframe in the included studies. CONCLUSIONS VSE combination therapy administered in cardiopulmonary resuscitation led to improved rates of ROSC. Future trials of VSE therapy should evaluate survival to hospital discharge, neurological function and long-term survival.</p>-
dc.languageeng-
dc.relation.ispartofJournal of Geriatric Cardiology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleEfficacy of vasopressin, steroid, and epinephrine protocol for in-hospital cardiac arrest resuscitation: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis -
dc.typeArticle-
dc.identifier.doi10.11909/j.issn.1671-5411.2022.09.002-
dc.identifier.scopuseid_2-s2.0-85143124997-
dc.identifier.hkuros343786-
dc.identifier.volume19-
dc.identifier.issue9-
dc.identifier.spage705-
dc.identifier.epage711-
dc.identifier.issnl1671-5411-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats